The Immunopathology of Psoriasis

International Archives of Allergy and Immunology

Volumn 110, Issue 3, 1996, Pages 199-206

  Christophers, Enno ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Cytokines; Disease association; Genetic heterogeneity; HLA; Lipid mediators; Psoriasis; T cells

Indexed keywords

CYTOKINE; GROWTH FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

CELL PROLIFERATION; EPITHELIUM CELL; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOPATHOLOGY; ONSET AGE; PRIORITY JOURNAL; PSORIASIS; REVIEW;

EID: 0029984050     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237288     Document Type: Article

References (81)

1. Christophers E, Stcrry W: Psoriasis; in Fitzpatrick TB, Eisen AZ, Wolff K, Frcedberg JM, Austen KF (eds): Dermatology in General Medicine, ed 4, New York, MacGraw-Hill, 1993.
2. Pinkus H, Mehregan AH: The primary histologic lesion of scborrhoic dermatitis and psoriasis, J Invest Dermatol 1966:46:109.
3. Chrilophers E, Kiene P: Guttate and plaque psoriasis, Dermatol Clin 1995:13:751-756.
4. Kanonen J: I IE-A antigens in psoriasis with special reference to the clinical type, age of onset, exacerbation after respiratory infection and occurence of arthritis, Ann Clin Res 1975:7: 301-311.
5. Svejgaard A, Staub Nielsen L, Svejgaard E, et al: HL-A in psoriasis vulgaris and in pustular psoriasis: Population and family studies, Br J Dermatol 1991;91:145-153.
6. Henseler T, Christophers E: Psoriasis of early and late onset: Characteriszation of two types of psoriasis vulgaris, J Am Acad Dermatol 1985; 13:450-456.
7. Schmidt-Egenolf M, Boehnckc W-H, Ständer M, Eiermann TH, Sterry W: Oligonucleotide typing reveals association of type I psoriasis with the HLA-DRB1*0701/2,-DQA1*0201, -DQB 1*0303extended haplotype, J Invest Dermatol1993;100:749-752.
8. Barker JN WN: The pathophysiology of psoriasis, Lancet 1991:338:227-230.
9. Krueger JG, Krane JF, Carter DM, Gottlieb AB: Role of growth factors, cytokines, and their re-ccp:ors in the pathogenesis of psoriasis, J Invest Dermatol 1990;94(suppl):135-140.
10. Schröder J-M: Inflammatory mediators and chemoattractants, Clin Dermatol 1995;14:137-150.
11. Gross WL, Packhäuser U, Hahn G, Westphal E, Christophers E, Sehlaak M: Lymphocyte activation by streptococcal antigens in psoriasis, Hr J Dermatol 1977;97:529-536.
12. Baker BS, Bokth S, Powles A, Garioch JJ, Lewis H, Valdimarsson H, Fry L: Group A streptococcal antigen-specific T lymphocytes in gut-tatc psoriatic lesions, Br.l Dermatol 1993:128: 493-499.
13. Targau SR, Murphy LK: Clarifying the causes of Crohn's disease, Nature Med 1985:1241 -1243.
14. Davies JL, Kawaguchi Y, Bennett ST, Copeman, IB, Cordell HJ, Pritchard LE, Reed PW, Gough SCL, Jenkins SC, Palmer SM, Balfour KM, Rowe BR, Farrall M, Barnett AI I, Bain SC, Todd JA: A genome-wide search for human type I diabetes susceptibility genes, Nature 1994;371:130-136.
15. Lomholt G: Psoriasis: Prevalence, Spontaneous Course, and Genetics, Copenhagen, Gads, 1993.
16. Brandrup F, Holm N, Grunnet N, Henningsen K, Hansen HE: Psoriasis in monozygotic twins: Variations in expression in individuals with identical genetic constitution, Acta Dermatol Venereol 1982:62:229-236.
17. Elder JT, Nair RP, Guo SW, Henseler T, Christophers F., Voorhees JJ: The genetics of psoriasis, Arch Dermatol 1994:130:216-224.
18. Tomfohrde J, Silverman A, Bantcs R, Feman-de-Vina MA, Young M, Lory D, Morris I., Wuepper KD, Stastny P, Mcnter A, Bowcock A: Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q, Science 1994:264:1141-1145.
19. Nair RP, Sun-Wei G, Jcnisch S, et al: Scanning chromosome 17 for psoriasis susceptibility: No evidence for a distal 17q locus, In press.
20. Christophers E, Henseler T: Psoriasis types I and II as subtypes of nonpustular psoriasis, Semin Dermatol 1992; 11:261-266.
21. Ozawa A, Ohkido M, Inoko FI, et al: Specific restriction fragment length polymorphism on the HLA-C region and susceptibility to psoriasis vulgaris, J Invest Dermatol 1988:90:402-405.
22. Asahina A, Akazaki S, Nakagawa H, et al: Specific nucleotide sequence of HLA-C is strongly associated with psoriasis vulgaris, .1 Invest Dermatol 1991;97:254-258.
23. Roitberg-Tambur A, Friedmann A, et al: Do specific pockets of HLA-C molecules predispose Jewish patients to psoriasis vulgaris? J Am Acad Dermatol 1994;31:964-968.
24. Ikähcimo I, Silvcnnoinen-Kassinen S, Karvo-nen I, Tiilikainen A: Alanine at position 73 of HLA-C is associated with psoriasis vulgaris in Finland, Br J Dermatol 1994; 131:257-259.
25. Henseler T, Christophers E: Disease concomitance in psoriasis, J Am Acad Dermatol 1995: 32:982-986.
26. Epstein WL, Maibach HI: Immunologic competence of patients with psoriasis receiving cytotoxic drug therapy, Arch Dermatol 1965:91
27. Fedler R, Strömer K: Nickel sensitivity in atopies, psoriatics and healthy subjects, Contact Dermatitis 1993;29:65-69.
28. Schubcrl C, Christophers E: Mast cells and macrophages in early relapsing psoriasis, Arch Dermatol Res 1985:277:352-358.
29. Gottlieb AB, Lifshitz B, Fu SM, Staiano-Coico L, Wang CY, Carter DM: Expression of HLA-DR molecules by kératinocytes and presence of Langcrhans cells in the dermal infiltrate of active psoriatic plaques, J Exp Med 1986:164: 1013-1028.
30. Gottlieb AB: Immunologic mechanisms in psoriasis, .J Am Acad Dermatol 1988; 18:1376-1380.
31. Nickoloff BJ, Turka LA, Mitra RS, et al: Direct and indirect control of T-ccll activation by kératinocytes, J Invest Dermatol 1995; 105(suppl): 25-29.
32. Gottlieb AB, Krueger JG: Role of T-lympho-cytes (in psoriasis pathogenesis): in Dubertret L (ed): Psoriasis, Brescia, ISED, 1994, pp 63-71.
33. Griffiths TW, Griffiths CEM, Voorhees JJ: Irn-munopathogenesis and immunotherapy of psoriasis, Dermatol Clin 1995;13:739-749.
34. Vallat VP, Gillcaudeau P, Battat L, Wolfe J, Na-beya R, Heftier N, Hodak E, Gottlieb AB, Krueger JG: PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy, J Exp Med 1994:180:283-296.
35. Baker BS, Swain AF, Griffiths EM, Leonard JN, Fry L, Valdimarsson H: Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: The effects of PUVA treatment, Clin Exp Immunol 1985:61:526.
36. Prinz J, Braun-Falco O, Meurer M, et al: Chi-maeric CD4 monoclonal antibody in treatment of generalised pustular psoriasis, Lancet 1991; 338:320-321.
37. Nicholas JF, Chauchick N, Thivolet J, et al: CD4 antibody treatment of severe psoriasis, Lancet 1991:338:321.
38. Funk J, Langeland T, Schrumpf E, Haussen LE: Psoriasis inducted by interferon-u, Br J Dermatol 1991:125:463-465.
39. Lee RE, Gaspari AA, Lotzc MT, Chang AE, Rosenberg SA: lnterleukin-2 and psoriasis, Arch Dermatol 1988:124:1811.
40. Griffiths CEM, Powdes AV, Leonard JN, et al: Clearance of psoriasis with low dose cyclosporin, BrJ Dermatol 1986:293:731-732.
41. Va Joost TH, Heule F, Stolz E, et al: Short term use of cyclosporin A in severe psoriasis, Br J Dermatol 1986:114:615-620.
42. Christophers E, Mrowietz U, Hcnneicke HH, Färber L, Welzcl D, the Participants in the German Multieender Study: Cyclosporinc in psoriasis: A multicentcr dose-finding study in severe plaque psoriasis, J Am Acad Dermatol 1992;26:86-90.
43. Mrowietz U, Färber L, Henneicke-von Zepelin H-H, et al: Long-term maintenance therapy with cyclsoporine and posttreatment survey in severe psoriasis: Results of a multicenter study, J Am Acad Dermatol 1995:33:470- 475.
44. Jegasothy BV, Ackerman CD, Todo S, Fung JJ, Abu-Elmagd K, Starzl TE: Tacrolimus (FK 506): A new therapeutic agent for severe recalcitrant psoriasis, Arch Dermatol 1992:128:781.
45. Eedy DJ, Burrows D, Bridges JM, Joncs FGC: Clearance of severe psoriasis after allogenic bone marrow transplantation, Br Med J 1990; 300:908.
46. Gardembas-Pain M, Ifrah N, Foussard C, Boas-son M, et al: Psoriasis after allogenic bone marrow transplantation, Arch Dermatol 1990:126: 1523.
47. mIL-2) suggests a primary immune, but not kératinocyte, pathogenic basis, Nature Med 1995:1:442.
48. Baadsgaard O, Fisher G, Fox DA, et al: Conditioned 'media from lesional psoriatic T-cell clones induces keratinocyte proliferation and expression of the surface activation molecule UM4D4 (abstract), Clin Res 1989:37:688.
49. Prinz JC, Gross B, Vollmer S, Trommler P, Strobel I, Meurer M, Plewig G: T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products, Eur J Immunol 1994:24:593- 598.
50. Strange P, Cooper KD, Hansen ER, Fisher G, Larsen JK, Fox D, Krag C, Joorhees JJ, Baadsgaard O: T lymphocyte clones from lesional psoriatic skin release growth factors that induce keratinocyte proliferation, J Invest Dermatol 1993:101:695.
51. Barker JNWN, Karabin GD, Stoof TJ, Sarma VJ, Dixit VM, Nickoloff BJ: Detection of in-tcrfcron-gamma mRNA in psoriatic epidermis by polymerase chain reaction, .J Dermatol Sci 1991;2:106-111.
52. Baadsgaard O, Tong P, Elder JT, et al: UM4D4+ (CDw60) T cells are compartmentalized into psoriatic skin and release lymphokines that induce a keratinocyte phenotype expressed in psoriatic lesions, J Invest Dermatol 1990:95: 275-282.
53. Hancock GE, Kaplan G, Colin ZA: Keratinocyte growth regulation by the products of immune cells, J Exp Med 1988;168:1395-1402.
54. Krueger G, Jorgensen C, Miller C, Schröder JM, Sticherling M, Christophers E: Effects of IL-8 on epidermal proliferation, .J Invest Dermatol 1990:94:545.
55. Chang JCC, Smith LR, Froning K.I, Schwabe BJ, Laxer JA, Caralli LL, Kurland HH, Karasek MA, Wilkinson DL, Carlo DJ, Brostoff SW: CD8+ T cells in psoriatic lesions preferentially use T-cell receptor Vß3 and/or Vβ131 genes, Proc Natl Acad Sci USA 1994:91, 9282-9286.
56. Boehncke WH, Küenzlen C, Zöllner TM, Miclkc V, et al: Predominant usage of distinct T-cell receptor Vb regions by cpidermotropic T cells in psoriasis, Exp Dermatol 1994:3:161- 163.
57. Lewis HM, Baker BS, Bokth S, Powles AV, Ge-rioch JJ, Valdimarsson H, Fry L: Restricted T-celi receptor Vi gene usage in the skin of patients with guttate and chronic plaque psoriasis, BrJ Dermatol 1993;129:514-520.
58. Leung DYM, Walsh P, Giomo R, et al: A potential role for supcrantigens in the pathogenesis ot psoriasis, J Invest Dermatol 1993:100:225-228.
59. Leung DYM, Travers IB, Giomo R, Norris DA, Skinner R, Aelion J, Kazemi LV, Kim MH, Trumble AE, Kotb M, Schlievert PM: Evidence fora streptococcal superantigen-driven process in acute guttatc psoriasis, J Clin Invest 1995;96: 2106-2112.
60. Menssen A, Trommler P, Vollmer S: Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris, J Immunol 1995:155:4078-4083.
61. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L: Psoriasis: A T-ccll mediated autoimmune disease induced by steptococcal superantigens? Immunol Today 1995;16:145-149.
62. Uyemura K, Yamamura M, Fivenson DF, Mo-dlin RL, Nickoloff BJ: The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type I cell-mediated response, J Invest Dermatol 1993;101:701-705.
63. Fierlbeck G, Rassner G: Treatment of psoriasis and psoriatic arthritis with interferon gamma, J Invest Dermatol 1990:95:138.
64. Schlaak JF, Buslau M, Jochum W, et al: T cells involved in psoriasis vulgaris belong to the Th 1 subset, J Invest Dermatol 1994:102:145-149.
65. Vollmer S, Menssen A, Trommler P, et al: T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type I and T helper type 2 cells, Eur J Immunol 1994:24:2377-2382.
66. Schröder JM, Sticherling M, Smid P, Christo-pers E: Interleukin 8 and structurally related cytokines: in Luger TA, Schwarz T (eds): Epidermal Growth Factors and Cytokines, New York, Dekker, 1993, pp 89-112.
67. Krueger JG, Krane JF, Carter DM, Gottlieb AB: Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis, J Invest Dermatol 1990:94(suppl): 135-140.
68. Nickoloff BJ: The cytokine network in psoriasis, Arch Dermatol 1991:127:871-884.
69. de Boer OJ, Wakelkamp IMMJ, Pals ST, Claes-scn N, Bos JD, Das PK: Increased expression of adhesion receptors in both lesional and non-le-sional psoriatic skin, Arch Dermatol 1994:286: 304-311.
70. Imhof BA, Dunon D: Leukocyte migration and adhesion, Adv Immunol 1995;58:345-416.
71. Picker LJ, Kishimoto TK, Smith CW, Wamock RA, Butcher EC: EL AM-1 is an adhesion molecule for skin-homing T cells, Nature 1991:349: 796-799.
72. Picker LJ, Mickie SA, Rott LS, Butcher EC: A unique phenotype of skin associated lymphocytes in humans, Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites, Am J Pathol 1990; 136: 1053-1068.
73. Rossitcr H, van Rcijsen F, Mudde GC, Kalthoff F, Bruijnzeel-Koomen CAFM, Picker LJ, Küpper TS: Skin disease-related T cells bind to endothelial selcctins: Expression of cutaneous lymphocyte antigen (CLA) predicts E-selectin but not P-sclectin binding, Eur J Immunol 1994: 24:205-210.
74. Camp RD, Bacon KB, Fincham NJ: Lymphocyte chemoattractants in psoriasis and normal skin, J Invest Dermatol 1990;95(suppl):22—23.
75. Taub DD, Lloyd AR, Conlon K, Wang JM, Or-taldo JR, Harada A, Matsushima K, Kelvin DJ, Oppenheim JJ: Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells, J Exp Med 1993;177:1809-1814.
76. Stieherling M, Schroder JM, Christophers E: Detection of NAP-l/IL-8 and related peptides from different sources by monoclonal antibodies; in Oppenheim JJ, Powanda MC, Kluger MJ, Dinarcllo CA (eds): Molecular and Cellular Biology of Cytokines, New York, Liss, 1990, pp 339-344.
77. Stieherling M, Bornscheuer E, Schröder JM, Christophers E: Localization of neutrophil activating peptide-1/interleukin-8 immunoreactiv-ity in normal and psoriatic skin, J Invest Dermatol 1991;96:26-30.
78. Kupper TS, Ballard DW, Chua AO.etal: Human kcratinocytes contain ntRNA indistinguishable from monocyte interleukin I alpha and beta mRNA.J Exp Med 1986;164:2095-2100.
79. Wiedow O, Schröder J-M, Gregory H, Young J, Christophers E: Elafin: An clastase-spccific inhibitor of human skin, J Biol Chem 1990:265: 14791-14795.
80. Schroder JM, Gregory H, Young J, Christophers E: Neutrophil-activating proteins in psoriasis, J Invest Dermatol 1992:98:241- 247.
81. Wiecow O, Wiese F, Streit V, Kalm C, Christophers E: Lesional elastase activity in psoriasis, contact dermatitis and atopic dermatitis, J Invest Dermatol 1992;99:306-309.